HHS awards $697M contract to Phlow Corp for US-based advanced API manufacturing

Contract Overview

Contract Amount: $696,665,954 ($696.7M)

Contractor: Phlow Corp.

Awarding Agency: Department of Health and Human Services

Start Date: 2020-05-18

End Date: 2027-01-13

Contract Duration: 2,431 days

Daily Burn Rate: $286.6K/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: COST PLUS FIXED FEE

Sector: Healthcare

Official Description: US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS.

Place of Performance

Location: RICHMOND, RICHMOND CITY County, VIRGINIA, 23219

State: Virginia Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $696.7 million to PHLOW CORP. for work described as: US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS. Key points: 1. Contract focuses on domestic production of essential medicines and preparedness for future threats. 2. Sole-source award raises questions about competition and potential for price optimization. 3. Long contract duration (2020-2027) suggests a strategic, long-term investment in supply chain resilience. 4. Cost-plus-fixed-fee structure may incentivize cost increases, requiring robust oversight. 5. The contract's success hinges on Phlow Corp's ability to establish and scale advanced manufacturing capabilities. 6. Geographic focus on Virginia for manufacturing operations.

Value Assessment

Rating: fair

Benchmarking the value of this contract is challenging due to its unique focus on domestic advanced API manufacturing for pandemic preparedness. The Cost Plus Fixed Fee (CPFF) pricing structure, while common for R&D and complex projects, can lead to higher costs compared to fixed-price contracts if not managed carefully. The total award of $697 million over approximately 7 years indicates a significant investment. Without comparable sole-source contracts for similar advanced manufacturing capabilities, a definitive value-for-money assessment is difficult, but the strategic importance of domestic supply chains may justify the investment.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning there was no open competition. This approach is typically used when a specific contractor possesses unique capabilities or when urgency dictates a rapid award. While it ensures Phlow Corp can proceed, it limits the government's ability to explore alternative solutions or leverage competitive pricing. The lack of competition means taxpayers may not benefit from the cost savings typically achieved through a bidding process.

Taxpayer Impact: The sole-source nature of this award means taxpayers did not benefit from competitive bidding, potentially leading to a higher overall cost than if multiple firms had competed for the contract.

Public Impact

The primary beneficiaries are US citizens, who will have increased access to domestically manufactured essential medicines. The contract aims to bolster the nation's preparedness for future public health emergencies and pandemics. Services delivered include the advanced manufacturing of Active Pharmaceutical Ingredients (APIs) for critical drugs. Geographic impact is concentrated in Virginia, where Phlow Corp's manufacturing facilities are located. Workforce implications include job creation in advanced manufacturing and pharmaceutical sciences within the US.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price discovery and potential taxpayer savings.
Cost-plus-fixed-fee contract type can lead to cost overruns if not closely monitored.
Reliance on a single contractor for critical API manufacturing poses supply chain risk.
Contract duration is long, requiring sustained oversight to ensure performance and adapt to evolving needs.

Positive Signals

Addresses critical national security need for domestic pharmaceutical manufacturing.
Aims to build resilient supply chains for essential medicines.
Focuses on advanced manufacturing capabilities, potentially fostering innovation.
Contract supports US-based jobs and economic development in the pharmaceutical sector.

Sector Analysis

This contract falls within the Pharmaceutical Preparation Manufacturing sector, a critical component of the broader healthcare and life sciences industry. The market for APIs is global, but this award specifically targets building domestic capacity. The US government has shown increasing interest in reshoring pharmaceutical manufacturing to mitigate risks exposed by global supply chain disruptions, particularly highlighted during the COVID-19 pandemic. Comparable spending benchmarks are difficult to establish due to the specialized nature of advanced API manufacturing and the strategic, non-commercial objectives of this contract.

Small Business Impact

This contract does not appear to include specific small business set-aside provisions. As a sole-source award to Phlow Corp, the direct impact on small businesses is limited unless Phlow Corp actively engages them as subcontractors. The success of this initiative could indirectly benefit the small business ecosystem by stimulating demand for specialized services and materials within the pharmaceutical supply chain, provided Phlow Corp prioritizes subcontracting opportunities.

Oversight & Accountability

Oversight for this contract is managed by the Department of Health and Human Services (HHS), specifically the Office of Assistant Secretary for Preparedness and Response (ASPR). As a Cost Plus Fixed Fee contract, rigorous financial oversight is crucial to monitor expenditures and ensure costs are reasonable and allocable. Transparency will depend on HHS's reporting practices and any public disclosures made regarding contract performance and spending. The Inspector General for HHS would likely have jurisdiction for audits and investigations.

Related Government Programs

Biomedical Advanced Research and Development Authority (BARDA) contracts
Strategic National Stockpile procurements
Operation Warp Speed initiatives
Defense Production Act investments in pharmaceutical manufacturing

Risk Flags

Sole Source Award
Cost-Plus Contract Type
Long Contract Duration
Critical Supply Chain Focus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $696.7 million to PHLOW CORP.. US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS.

Who is the contractor on this award?

The obligated recipient is PHLOW CORP..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $696.7 million.

What is the period of performance?

Start: 2020-05-18. End: 2027-01-13.

What is Phlow Corp's track record in advanced API manufacturing and large-scale government contracting?

Phlow Corp was founded in 2020 with the explicit goal of addressing the US pharmaceutical supply chain. While the company has attracted significant investment and partnerships, its track record in large-scale, long-term government contracting for advanced API manufacturing is nascent, given its recent establishment. The company's strategy involves building domestic manufacturing capabilities, including through partnerships and acquisitions. Its ability to execute on this substantial contract will be a key determinant of its future success and a critical factor for HHS to monitor closely. Information on prior large-scale government contracts specifically for API manufacturing is limited, underscoring the developmental nature of this engagement.

How does the pricing structure (Cost Plus Fixed Fee) compare to market rates for similar advanced manufacturing services?

The Cost Plus Fixed Fee (CPFF) pricing structure is common for research, development, and complex manufacturing projects where costs are difficult to estimate upfront. It allows the contractor to recover all allowable costs plus a predetermined fixed fee representing profit. While this structure provides flexibility and incentivizes the contractor to perform, it can lead to higher overall costs compared to fixed-price contracts if cost controls are not robust. Benchmarking CPFF rates for advanced API manufacturing is challenging due to the specialized nature of the work and the strategic objectives of this contract. However, government agencies typically scrutinize costs closely under CPFF agreements to ensure they are reasonable and necessary, often requiring detailed cost proposals and ongoing audits.

What are the primary risks associated with relying on a sole-source award for critical medicine manufacturing?

The primary risks associated with a sole-source award for critical medicine manufacturing include a lack of competitive pressure, which can lead to higher prices and potentially less innovation. It also concentrates risk with a single supplier; if Phlow Corp faces production issues, delays, or financial instability, the entire domestic supply chain for these essential medicines could be jeopardized. Furthermore, the government has limited leverage to negotiate better terms or explore alternative solutions without a competitive process. This necessitates extremely diligent oversight by HHS to ensure performance, quality, and cost-effectiveness throughout the contract's duration.

How will the success of this contract be measured in terms of ensuring future pandemic preparedness?

The success of this contract will be measured by several key performance indicators (KPIs) related to establishing and maintaining robust domestic manufacturing capabilities for essential medicines and APIs. This includes the successful scale-up of production, meeting quality and regulatory standards, ensuring timely delivery of products, and demonstrating the ability to rapidly pivot to manufacturing new or prioritized medicines as needed for future threats. Metrics will likely track production volumes, cost efficiency over time, supply chain resilience indicators, and the successful transfer of technology and knowledge. HHS's ASPR will be responsible for monitoring these KPIs and ensuring Phlow Corp meets its contractual obligations to enhance national preparedness.

What is the historical spending pattern for domestic API manufacturing initiatives by HHS?

HHS, particularly through agencies like BARDA, has historically invested in initiatives aimed at strengthening domestic pharmaceutical manufacturing capabilities, especially in response to public health emergencies. However, large, long-term, sole-source contracts specifically for advanced API manufacturing at this scale are less common. Much of the historical spending has been through grants, cooperative agreements, or competitively awarded contracts for specific drug development or manufacturing projects. The COVID-19 pandemic significantly accelerated the focus on supply chain security, leading to increased investments and a greater willingness to explore various contracting mechanisms, including sole-source awards, to rapidly build domestic capacity, making this contract a notable departure from some previous patterns.

What are the potential implications of this contract on the broader US pharmaceutical manufacturing landscape?

This contract has the potential to significantly reshape the US pharmaceutical manufacturing landscape by catalyzing the development of advanced API production facilities domestically. It signals a strategic government commitment to reducing reliance on foreign supply chains, which could encourage further private investment in similar capabilities. By focusing on advanced manufacturing techniques and preparedness for future threats, it may also drive innovation and the adoption of new technologies within the sector. The success of Phlow Corp could serve as a model for other domestic manufacturing initiatives, potentially leading to a more resilient and secure pharmaceutical supply chain for the nation.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: BAA-18-100-SOL-00003

Offers Received: 1

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 737 N 5TH ST STE 605, RICHMOND, VA, 23219

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Self-Certified Small Disadvantaged Business, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $969,754,682

Exercised Options: $708,849,576

Current Obligation: $696,665,954

Actual Outlays: $560,161,834

Subaward Activity

Number of Subawards: 2

Total Subaward Amount: $24,734,874

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline